Thymmune Therapeutics is a technology company.
Thymmune Therapeutics has raised $7.0M across 1 funding round.
Thymmune Therapeutics has raised $7.0M in total across 1 funding round.
Thymmune Therapeutics has raised $7.0M in total across 1 funding round.
Thymmune Therapeutics's investors include Catalio Capital, Flagship Ventures, Third Rock Ventures.
Thymmune Therapeutics is a preclinical biotechnology company developing a machine learning-driven platform for thymic cell engineering to restore immune function in patients with immunodeficiencies, transplant-related issues, autoimmune disorders, and age-related immune decline.[1][2] It produces scalable, off-the-shelf iPSC-derived thymic cells, targeting conditions like athymia through therapies such as THY-001, which differentiates thymic epithelial progenitor cells (TEPs) into functional thymic tissues.[2][5] Based in Cambridge, Massachusetts, the company has raised over $600 million in funding, including a $380 million Series C in 2023 that valued it at $1 billion, demonstrating strong growth momentum fueled by seed ($7 million), Series A ($13 million), and government support like a $1 million SBIR Phase II award.[1][2][5]
Founded in 2019 in Cambridge, Massachusetts, Thymmune emerged from decades of research on the thymus gland, a critical immune organ that declines with age and disease, leading to vulnerabilities like immunodeficiencies.[1][2] The idea leverages proprietary insights in thymic engineering, using iPSC-derived cells to regenerate thymic function in a scalable way, addressing gaps in current treatments.[4][5] Early traction included $7 million in seed funding led by Pillar VC and NYBC Ventures in 2021, followed by $13 million to advance preclinical studies, and recent bolstering of its leadership with biopharmaceutical veterans, including head of corporate development Supratim Das.[1][2] Pivotal moments include ARPA-H funding as the first industry project under its Open Broad Agency Announcement and an SBIR Fast Track grant to optimize THY-001 production for clinical trials.[2][5]
Thymmune rides the wave of regenerative immunology and iPSC cell therapy, a booming sector addressing the global rise in immune disorders from aging populations, transplants, and autoimmunity—market forces amplified by advances in AI-driven biomanufacturing and stem cell scalability.[1][2] Timing is ideal amid surging biotech investments in "off-the-shelf" cell therapies, which reduce costs and patient wait times compared to autologous methods, positioning Thymmune to influence healthier aging and post-transplant care ecosystems.[2][5] As part of NYBC Ventures' focus on blood and cell therapies, it fosters partnerships with research labs and accelerates innovation in transfusion medicine and infectious disease responses.[3]
Thymmune is primed to advance THY-001 into IND-enabling studies and clinical trials, leveraging its SBIR progress and $600 million war chest to scale manufacturing and test in large preclinical models.[1][5] Trends like AI-optimized cell engineering and ARPA-H-backed projects will shape its path, potentially expanding to Phase 1 trials by 2026-2027 for athymia and beyond. Its influence could evolve into a leader in thymic rejuvenation, transforming immune restoration from niche to standard care and enabling broader applications in aging biotech. This positions Thymmune as a high-momentum player restoring immune resilience at scale.
Thymmune Therapeutics has raised $7.0M across 1 funding round. Most recently, it raised $7.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $7.0M Seed | Catalio Capital, Flagship Ventures, Third Rock Ventures |